Teva To Present New Data Supporting Safety, Efficacy And Real-World Effectiveness Of AUSTEDO Tablets At The 2023 HSG Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced new data supporting the safety, efficacy, and real-world effectiveness of AUSTEDO tablets for treating Huntington's disease (HD) chorea. The data will be presented at the Huntington Study Group® (HSG) Annual Meeting. The results show that 92% of patients achieved optimal dosing by week 12 with the AUSTEDO 4-week patient titration kit. The data also reinforce the efficacy and tolerability of AUSTEDO.

November 02, 2023 | 12:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Teva Pharmaceuticals announced new data supporting the safety and efficacy of AUSTEDO tablets for treating Huntington's disease. This could potentially boost the company's reputation and sales.
The announcement of positive data regarding the safety and efficacy of AUSTEDO tablets could potentially increase the demand for the drug, leading to increased sales and a positive impact on Teva's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100